SLC5A2 and diabetic ketoacidosis: Moreover, a nationwide register-based cohort study from two countries found that the use of SGLT2 inhibitors compared with Glucagon Like Peptide-1 receptor agonists was associated with a 2.1-fold increased risk of diabetic ketoacidosis (95%CI 1.01–4.52) in T2DM patients [21].